An Efficacy and Safety Study of Telaprevir in Patients Infected With Both Chronic Hepatitis C Virus (HCV-1) and Human Immunodeficiency Virus (HIV-1)
Phase 3
Completed
- Conditions
- Chronic Hepatitis C
- Interventions
- First Posted Date
- 2012-01-20
- Last Posted Date
- 2016-05-05
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 163
- Registration Number
- NCT01513941
Early Access Program of Telaprevir With Peginterferon and Ribavirin in Chronic Hepatitis C Subjects
- Conditions
- Hepatitis C
- First Posted Date
- 2012-01-11
- Last Posted Date
- 2015-07-24
- Lead Sponsor
- Janssen-Cilag International NV
- Registration Number
- NCT01508286
Telaprevir Open-Label Study in Co-Infected Patients
- First Posted Date
- 2011-12-28
- Last Posted Date
- 2016-08-18
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 122
- Registration Number
- NCT01500616
Open-Label, Bridging Study of Telaprevir in Treatment-Naïve and Treatment-Experienced Russian Patients With Genotype 1 Chronic Hepatitis C
Phase 3
Completed
- Conditions
- Genotype 1 Chronic Hepatitis C
- Interventions
- First Posted Date
- 2011-12-23
- Last Posted Date
- 2015-01-30
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 36
- Registration Number
- NCT01498068
A Clinical Trial Comparing the Efficacy of Darunavir/Ritonavir Monotherapy Versus a Triple Combination Therapy Containing Darunavir/Ritonavir and 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors in Patients With Undetectable Plasma HIV-1 RNA on Current Treatment
Phase 3
Completed
- Conditions
- Acquired Immunodeficiency Syndrome (AIDS) VirusHuman Immunodeficiency Virus (HIV) Infections
- Interventions
- First Posted Date
- 2011-10-07
- Last Posted Date
- 2017-11-27
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 274
- Registration Number
- NCT01448707
An Efficacy Study for Epoetin Alfa in Anemic Patients With Myelodysplastic Syndromes
Phase 3
Completed
- Conditions
- Myelodysplastic Syndromes
- First Posted Date
- 2011-06-27
- Last Posted Date
- 2016-03-16
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 130
- Registration Number
- NCT01381809
A Safety, Tolerability, Pharmacokinetics, and Immunogenicity Study of CNTO 6785 in Healthy Volunteers
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: CNTO 6785 1 mg/kg IVDrug: CNTO 6785 3 mg/kg IVDrug: Placebo IVDrug: CNTO 6785 10 mg/kg IVDrug: CNTO 6785 SCDrug: Placebo SC
- First Posted Date
- 2011-02-02
- Last Posted Date
- 2013-01-28
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 32
- Registration Number
- NCT01288196
Velcade Consolidation Bone Study
- First Posted Date
- 2011-01-31
- Last Posted Date
- 2016-05-30
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 106
- Registration Number
- NCT01286077
Paliperidone Palmitate Flexible Dosing in Schizophrenia
- First Posted Date
- 2011-01-24
- Last Posted Date
- 2014-03-10
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 1044
- Registration Number
- NCT01281527
Prevention of Relapse With Injectable Paliperidone Palmitate Versus Oral Antipsychotics
Phase 3
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: oral antipsychotics
- First Posted Date
- 2010-03-05
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 769
- Registration Number
- NCT01081769